Late-life depression (LLD) is a prevalent and disabling condition in older adults that is often accompanied by slowed processing and gait speed. These symptoms are related to impaired dopamine function and sometimes remedied by levodopa (L-DOPA). In this study, we recruited 33 older adults with LLD to determine the association between a proxy measure of dopamine function—neuromelanin-sensitive magnetic resonance imaging (NM-MRI)—and baseline slowing measured by the Digit Symbol test and a gait speed paradigm. In secondary analyses, we also assessed the ability of NM-MRI to predict L-DOPA treatment response in a subset of these patients (N = 15) who received 3 weeks of L-DOPA. We scanned a further subset of these patients (N = 6) with NM-MRI at baseline and after treatment to preliminarily evaluate the effects of L-DOPA treatment on the NM-MRI signal. We found that lower baseline NM-MRI correlated with slower baseline gait speed (346 of 1807 substantia nigra–ventral tegmental area (SN-VTA) voxels, Pcorrected = 0.038), particularly in the more medial, anterior, and dorsal SN-VTA. Secondary analyses failed to show an association between baseline NM-MRI and treatment-related changes in gait speed, processing speed, or depression severity (all Pcorrected > 0.361); we however found preliminary evidence of increases in the NM-MRI signal 3 weeks post-treatment with L-DOPA compared to baseline (200 of 1807 SN-VTA voxels; Pcorrected = 0.046), although the small sample size of these preliminary analyses warrants caution in their interpretation and future replications. Overall, our findings indicate that NM-MRI is sensitive to variability in gait speed in patients with LLD, suggesting this non-invasive MRI measure may provide a promising marker for dopamine-related psychomotor slowing in geriatric neuropsychiatry.
Subscribe to Journal
Get full journal access for 1 year
only $30.69 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Friedhoff AJ, Ballenger J, Bellack AS, Carpenter WT Jr, Chui HC, Dobrof R, et al. Diagnosis and treatment of depression in late life. JAMA 1992;268:1018–24.
Rothschild AJ. The diagnosis and treatment of late-life depression. J Clin Psychiatry. 1996;57:5–11.
Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Feder M, Einhorn A, et al. Recovery in geriatric depression. Arch Gen Psychiatry. 1996;53:305–12.
Sneed JR, Rutherford BR, Rindskopf D, Lane DT, Sackeim HA, Roose SP. Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry. 2008;16:65–73.
Sheline YI, Barch DM, Garcia K, Gersing K, Pieper C, Welsh-Bohmer K, et al. Cognitive function in late life depression: relationships to depression severity, cerebrovascular risk factors and processing speed. Biol psychiatry. 2006;60:58–65.
Brown PJ, Roose SP, Zhang J, Wall M, Rutherford BR, Ayonayon HN, et al. Inflammation, depression, and slow gait: a high mortality phenotype in later life. J Gerontol Ser A Biomed Sci Med Sci. 2016;71:221–7.
Rutherford BR, Taylor WD, Brown PJ, Sneed JR, Roose SP. Biological aging and the future of geriatric psychiatry. J Gerontol Ser A Biomed Sci Med Sci. 2017;72:343–52.
Pimontel MA, Culang‐Reinlieb ME, Morimoto SS, Sneed JR. Executive dysfunction and treatment response in late‐life depression. Int J Geriatr psychiatry. 2012;27:893–9.
Kerse N, Flicker L, Pfaff JJ, Draper B, Lautenschlager NT, Sim M, et al. Falls, depression and antidepressants in later life: a large primary care appraisal. PLoS ONE. 2008;3:e2423.
Wolinsky FD, Callahan CM, Fitzgerald JF, Johnson RJ. Changes in functional status and the risks of subsequent nursing home placement and death. J Gerontol. 1993;48:S94–101.
Rutherford BR, Slifstein M, Chen C, Abi-Dargham A, Brown PJ, Wall MW, et al. Effects of L-DOPA monotherapy on psychomotor speed and [11C] raclopride binding in high-risk older adults with depression. Biol Psychiatry. 2019;86:221–9.
Rapp MA, Reischies FM. Attention and executive control predict Alzheimer disease in late life: results from the Berlin Aging Study (BASE). Am J Geriatr Psychiatry. 2005;13:134–41.
Verghese J, Holtzer R, Lipton RB, Wang C. Quantitative gait markers and incident fall risk in older adults. J Gerontol A Biol Sci Med Sci 2009;64:896–901.
Guralnik JM, Ferrucci L, Pieper CF, Leveille SG, Markides KS, Ostir GV, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55:M221–31.
Bäckman L, Nyberg L, Lindenberger U, Li S-C, Farde L. The correlative triad among aging, dopamine, and cognition: current status and future prospects. Neurosci Biobehav Rev. 2006;30:791–807.
Volkow ND, Gur RC, Wang G-J, Fowler JS, Moberg PJ, Ding Y-S, et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiat. 1998;155:344–9.
Kaasinen V, Vilkman H, Hietala J, Någren K, Helenius H, Olsson H, et al. Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging. 2000;21:683–8.
Eckart C, Bunzeck N. Dopamine modulates processing speed in the human mesolimbic system. Neuroimage 2013;66:293–300.
Cham R, Studenski S, Perera S, Bohnen N. Striatal dopaminergic denervation and gait in healthy adults. Exp Brain Res. 2008;185:391–8.
Cassidy CM, Zucca FA, Girgis RR, Baker SC, Weinstein JJ, Sharp ME, et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci USA. 2019;116:5108–17.
Chen X, Huddleston DE, Langley J, Ahn S, Barnum CJ, Factor SA, et al. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. Magn Reson imaging. 2014;32:1301–6.
Zucca FA, Basso E, Cupaioli FA, Ferrari E, Sulzer D, Casella L, et al. Neuromelanin of the human substantia nigra: an update. Neurotox Res. 2014;25:13–23.
Zecca L, Shima T, Stroppolo A, Goj C, Battiston G, Gerbasi R, et al. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 1996;73:407–15.
Zecca L, Bellei C, Costi P, Albertini A, Monzani E, Casella L, et al. New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc Natl Acad Sci USA 2008;105:17567–72.
Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res. 1999;1:181–95.
Wechsler D. The Wechsler Memory Scale. San Antonio: Psychological Corp. Harcourt; 1997
Wengler K, He X, Abi-Dargham A, Horga G. Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses. NeuroImage 2020;208:116457.
Slinker BK, Glantz SA. Multiple linear regression: accounting for multiple simultaneous determinants of a continuous dependent variable. Circulation. 2008;117:1732–7.
Eklund A, Nichols TE, Knutsson H. Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates. Proc Natl Acad Sci USA. 2016;113:7900–5.
Hupfeld KE, Vaillancourt DE, Seidler RD. Genetic markers of dopaminergic transmission predict performance for older males but not females. Neurobiol Aging. 2018;66:180.
Rosano C, Metti AL, Rosso AL, Studenski S, Bohnen NI. Influence of striatal dopamine, cerebral small vessel disease, and other risk factors on age-related parkinsonian motor signs. J Geront A Biol Sci Med Sci. 2019;75:696–701.
Rosso AL, Bohnen NI, Launer LJ, Aizenstein HJ, Yaffe K, Rosano C. Vascular and dopaminergic contributors to mild parkinsonian signs in older adults. Neurology. 2018;90:e223–9.
Clark BC, Woods AJ, Clark LA, Criss CR, Shadmehr R, Grooms DR. The aging brain & the dorsal basal ganglia: implications for age-related limitations of mobility. Adv Geriatr Med Res. 2019;1:e190008.
Salthouse TA. Aging and measures of processing speed. Biol Psychol. 2000;54:35–54.
Nyberg L, Karalija N, Salami A, Andersson M, Wåhlin A, Kaboovand N, et al. Dopamine D2 receptor availability is linked to hippocampal–caudate functional connectivity and episodic memory. Proc Natl Acad Sci USA. 2016;113:7918–23.
Vriend C, van Balkom TD, van Druningen C, Klein M, van der Werf YD, Berendse HW, et al. Processing speed is related to striatal dopamine transporter availability in Parkinson’s disease. NeuroImage Clin. 2020;26:102257.
Jaeger J. Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharmacol. 2018;38:513.
Seidler RD, Bernard JA, Burutolu TB, Fling BW, Gordon MT, Gwin JT, et al. Motor control and aging: links to age-related brain structural, functional, and biochemical effects. Neurosci Biobehav Rev. 2010;34:721–33.
Corti EJ, Johnson AR, Riddle H, Gasson N, Kane R, Loftus AM. The relationship between executive function and fine motor control in young and older adults. Hum Mov Sci. 2017;51:41–50.
LeMoult J, Gotlib IH. Depression: a cognitive perspective. Clin Psychol Rev. 2019;69:51–66.
Li C-T, Lin C-P, Chou K-H, Chen I-Y, Hsieh J-C, Wu C-L, et al. Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study. Neuroimage. 2010;50:347–56.
Yaroslavsky I, Allard ES, Sanchez-Lopez A. Can’t look away: attention control deficits predict rumination, depression symptoms and depressive affect in daily life. J Affect Disord. 2019;245:1061–9.
Shura RD, Rowland JA, Martindale SL, Brearly TW, Delahanty MB, Miskey HM. Evaluating the motor slowing hypothesis of depression. Psychiatry Res. 2017;252:188–95.
Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson’s disease. FEBS Lett. 2002;510:216–20.
Tison F, Mons N, Geffard M, Henry P. The metabolism of exogenous L-dopa in the brain: an immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain. J Neural Transm Park Dis Dement Sect. 1991;3:27–39.
Matsuura K, Maeda M, Tabei K-i, Umino M, Kajikawa H, Satoh M, et al. A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson’s disease. Neurosci Lett. 2016;633:112–7.
Sulzer D, Cassidy C, Horga G, Kang UJ, Fahn S, Casella L, et al. Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease. npj Parkinson’s Dis. 2018;4:11.
Damier P, Hirsch E, Agid Y, Graybiel A. The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain. 1999;122:1437–48.
Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114:2283–301.
Ofori E, Pasternak O, Planetta PJ, Burciu R, Snyder A, Febo M, et al. Increased free water in the substantia nigra of Parkinson’s disease: a single-site and multi-site study. Neurobiol Aging. 2015;36:1097–104.
Planetta PJ, Ofori E, Pasternak O, Burciu RG, Shukla P, DeSimone JC, et al. Free-water imaging in Parkinson’s disease and atypical parkinsonism. Brain. 2016;139:495–508.
Xiang Y, Gong T, Wu J, Li J, Chen Y, Wang Y, et al. Subtypes evaluation of motor dysfunction in Parkinson’s disease using neuromelanin-sensitive magnetic resonance imaging. Neurosci Lett. 2017;638:145–50.
Sulzer D, Bogulavsky J, Larsen KE, Behr G, Karatekin E, Kleinman MH, et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci USA. 2000;97:11869–74.
Cebrián C, Zucca FA, Mauri P, Steinbeck JA, Studer L, Scherzer CR, et al. MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun. 2014;5:3633.
Zucca FA, Segura-Aguilar J, Ferrari E, Muñoz P, Paris I, Sulzer D, et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson’s disease. Prog Neurobiol. 2017;155:96–119.
Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, et al. Neuromelanin can protect against iron‐mediated oxidative damage in system modeling iron overload of brain aging and Parkinson’s disease. J Neurochem. 2008;106:1866–75.
Zecca L, Wilms H, Geick S, Claasen J-H, Brandenburg L-O, Holzknecht C, et al. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson’s disease. Acta Neuropathol. 2008;116:47–55.
Rutherford BR, Wall MM, Brown PJ, Choo T-H, Wager TD, Peterson BS, et al. Patient expectancy as a mediator of placebo effects in antidepressant clinical trials. Am J Psychiat. 2017;174:135–42.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Wengler, K., Ashinoff, B.K., Pueraro, E. et al. Association between neuromelanin-sensitive MRI signal and psychomotor slowing in late-life depression. Neuropsychopharmacol. 46, 1233–1239 (2021). https://doi.org/10.1038/s41386-020-00860-z